Sunday, May 22, 2016 12:04:05 PM
Just looking at company's intellectual property and patents (over 28 issued and pending) for oncology delivery technology and orphan drug candidates, CLRB is a prime candidate for a buyout from big pharma companies.
http://files.shareholder.com/downloads/AMDA-2J5XQ5/2095683252x0x858018/9306EF62-5DF0-43FC-A5D4-94AA08E7E7A7/CLRB_Corporate_Presentation-1-11-16_F.pdf
“We are convinced that Cellectar’s proprietary technology will provide our cytotoxic molecules with
tissue specificity and enhanced safety which are typically lacking with untargeted agents.”
- Laurent Audoly, Head of R&D of Pierre Fabre Pharmaceuticals (Dec., 2015) p.22 from PDF presentation.
Also see page 23 for upcoming company events in Q2 2016, so not a good time to short CLRB or please do so at your own peril, that way longs can see a nice sizable squeeze when news comes out, LOL!
http://www.nasdaq.com/symbol/clrb
NASDAQ shows market cap. of approx. $13.2 million / $3.45 share price, so common stock outstanding is approx 3.8 million as of last Friday.
So what is this company's intellectual property and orphan drugs really worth with to big pharma? Worst $150-300 million and 500-800 million at best? This is chump change to the big players.
You do the math...
Recent CLRB News
- Form DEFR14A - Revised definitive proxy soliciting materials • Edgar (US Regulatory) • 05/16/2024 10:05:03 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 10:45:17 AM
- Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update • GlobeNewswire Inc. • 05/14/2024 10:40:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 10:32:20 AM
- Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day • GlobeNewswire Inc. • 05/08/2024 10:40:23 AM
- Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024 • GlobeNewswire Inc. • 05/07/2024 10:40:00 AM
- Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update • GlobeNewswire Inc. • 03/27/2024 10:40:00 AM
- Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024 • GlobeNewswire Inc. • 03/20/2024 10:40:00 AM
- Cellectar Biosciences to Present at the 36th Annual Roth Conference • GlobeNewswire Inc. • 03/14/2024 12:52:48 PM
- Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer • GlobeNewswire Inc. • 03/04/2024 11:40:00 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/15/2024 01:31:57 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:29:43 PM
- Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/07/2024 11:40:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 11:03:04 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/31/2024 01:00:28 PM
- Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study • GlobeNewswire Inc. • 01/30/2024 11:40:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:30:40 PM
- Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million • GlobeNewswire Inc. • 01/25/2024 11:40:00 AM
- Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient • GlobeNewswire Inc. • 01/22/2024 11:40:00 AM
- Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data • GlobeNewswire Inc. • 01/16/2024 11:40:00 AM
- Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results • GlobeNewswire Inc. • 01/12/2024 11:44:16 AM
- Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting • GlobeNewswire Inc. • 01/11/2024 11:40:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 11:02:18 AM
- Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia • GlobeNewswire Inc. • 01/08/2024 11:30:00 AM
- Cellectar Biosciences to Announce Top-line Data from WM Pivotal Trial on January 8, 2024 • GlobeNewswire Inc. • 01/03/2024 01:30:00 PM
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM
HealthLynked Corp Announces First Quarter 2024 Results: Achieves 8% Revenue Growth Over Last Quarter • HLYK • May 16, 2024 8:00 AM